Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Warner Chilcott Clear all

Conditions: Ulcerative Colitis
Interventions: Asacol 400 mg; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more

Conditions: Postmenopausal Vulvovaginal Atrophy
Interventions: WC3011 Estradiol Vaginal Cream, Vehicle; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 70
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more

Conditions: Pelvic Pain, Headaches, Emotional
Interventions: loestrin 24/4 vs loestrin 1/20, loestrin 1/20; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Osteopenia, Osteoporosis
Interventions: risedronate, alendronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Gainesville, Florida • New Orleans, Louisiana

Conditions: Ulcerative Colitis
Interventions: Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine); Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 54
States / cities: Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more

Conditions: Osteoporosis
Interventions: risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more

Conditions: Postmenopausal Osteoporosis
Interventions: Not listed
Lead sponsor: Warner Chilcott; Industry
Eligibility: Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more

Conditions: Ulcerative Colitis
Interventions: Mesalamine Once-Daily, Mesalamine Twice-Daily; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years and older
Enrollment: 1,027 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 233
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more

Conditions: Postmenopausal, Non-lactating, Surgically Sterile
Interventions: risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Gainesville, Florida • Miramar, Florida • Austin, Texas

Conditions: Osteoporosis
Interventions: risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet); Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 6
States / cities: San Diego, California • Fort Myers, Florida • Miramar, Florida + 3 more

Conditions: Urogential Chlamydia Trachomatis Infection
Interventions: Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 43
States / cities: Birmingham, Alabama • Foley, Alabama • Tucson, Arizona + 38 more

Conditions: Postmenopausal
Interventions: risedronate, experimental; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 4
States / cities: Daytona Beach, Florida • Gainesville, Florida • Shawnee Mission, Kansas + 1 more

Conditions: Osteogenesis Imperfecta
Interventions: risedronate sodium (Actonel), Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 4 Years to 15 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Omaha, Nebraska • New York, New York + 2 more

Conditions: Erectile Dysfunction
Interventions: WC3036-11F/Alprostadil in Vehicle 2.5%, WC3036-12F/Alprostadil in Vehicle 0.5%, WC3036-13P/Vehicle Only 0.5%; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Purchase, New York

Conditions: Osteoporosis
Interventions: Risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 4
States / cities: Gainesville, Florida • Miramar, Florida • Austin, Texas + 1 more

Conditions: Osteoporosis, Osteopenia
Interventions: FRAX Assessment Tool; Other
Lead sponsor: Duquesne University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Contraception
Interventions: Norethindrone acetate/ethinyl estradiol; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,683 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 66
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 1,271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 115
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 97 more

Conditions: Healthy
Interventions: Asacol, Lialda; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ulcerative Colitis
Interventions: Mesalamine; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 772 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 78
States / cities: Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 74 more

Conditions: Hormone Replacement Therapy
Interventions: Estradiol acetate, Estradiol, Conjugated equine estrogens; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 32
States / cities: Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more

Conditions: Spermatogenesis, Erectile Dysfunction
Interventions: Placebo, Udenafil; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 25 Years to 64 Years · Male only
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Huntsville, Alabama • Anaheim, California • San Diego, California + 19 more

Conditions: Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions: Estradiol Vaginal Capsule (EVC), Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more

Conditions: Neurogenic Detrusor Overactivity
Interventions: Darifenacin; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 9
States / cities: San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more

Search by objective public record fields.

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

A Comparison of Once a Day Dose Compared to 2 Doses/Day

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

Effect of Assessing Risk for Osteoporosis on Physician and Patient Behaviors

Study of Safety and Efficacy of an Oral Contraceptive

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

A Double Blind Study for the Treatment of Acute Ulcerative Colitis

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

Effect of Udenafil on Spermatogenesis

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity